SITC 2019 preview – Pieris joins the quest for a better Herceptin
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Breaking down Beigene’s latest deal with the west
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
Upcoming events – key tests approach for Kadmon and Surface
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
Triple meeting – Mirati avoids the worst-case scenario
Like AMG 510, MRTX849 yields partial responses in some lung and colorectal tumours, but investors could have expected better.
Another robot deal for J&J shows up lack of Verb results
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Triple meeting – targeted focus validates Merus’s change of tack
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
Astra guns for quick cancer and lupus filings
Questions about clinical data aside, Imfinzi and tremelimumab could be filed for first-line lung cancer by the end of the year.
Bristol might play a role in front-line lung cancer after all
The Checkmate-9LA trial of Opdivo plus Yervoy yesterday read out positively for overall survival.
Vindication is sweet for Seattle
Tucatinib yields a positive result in breast cancer, vindicating Seattle Genetics’ acquisition of its originator.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.